Novel agents for treating severe hypertriglyceridemia

Med. 2024 Dec 13;5(12):1446-1448. doi: 10.1016/j.medj.2024.10.019.

Abstract

The PALISADE trial extended the data available for inhibition of apolipoprotein (apo) C3 inhibition for treating severe hypertriglyceridemia.1 75 patients with persistent chylomicronemia were allocated to 2 doses of plozasiran or placebo. Triglycerides were reduced by a net 53%-58%, and a borderline significant 17% reduction was seen in pancreatitis events. These results offer potential treatments for familial or multifactorial chylomicronemia syndromes.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Apolipoprotein C-III / antagonists & inhibitors
  • Apolipoprotein C-III / blood
  • Benzimidazoles
  • Female
  • Humans
  • Hypertriglyceridemia* / blood
  • Hypertriglyceridemia* / drug therapy
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / pharmacology
  • Hypolipidemic Agents / therapeutic use
  • Male
  • Middle Aged
  • Pancreatitis / blood
  • Pancreatitis / drug therapy
  • Triglycerides / blood

Substances

  • Triglycerides
  • BMS201038
  • Apolipoprotein C-III
  • Hypolipidemic Agents
  • Benzimidazoles